GOLD guidelines adherence impact on the NHS budget

Alessandro Guasconi, Claudio Ripellino, Franca Heiman

DOI: https://doi.org/10.7175/fe.v15i1.887

Abstract

OBJECTIVE: Aim of this study was the evaluation of the adherence level to GOLD guidelines for the COPD patients’ treatment in the Italian GPs setting, observing the time trend on ICS therapies’ pharmacoutilization, specifically in mild and moderate COPD patients, which is considered inappropriate by GOLD guidelines. Moreover, a pharmacoeconomic analysis has been implemented in order to evaluate the economical burden of the improper management of COPD.
METHODS: The retrospective GPs database study has analyzed patients with at least one diagnosis of COPD during the periods January 2005 – December 2008 (Cohort 1) and January 2009 – December 2011 (Cohort 2), who had a reported value of VEMS, at least one prescription of a drug from ATC R03 class within two months from the date of spirometric exam and aged 40 or more. Disease severity has been defined according to 2008 GOLD guidelines. Comparison between the cohorts has been implemented to verify possible variations in guideline adherence. Furthermore, an economical analysis has been developed in order to highlight saves obtained by following GOLD guidelines and the total inappropriate therapies’ costs.
RESULTS: The first cohort involved 2,103 COPD patients, while the second cohort included 1,647 subjects. Reduction of ICS therapies has been shown between the two cohorts, with a decrease of 8.4% for mild patient and 1.6% for moderate patients; considering all the disease severities, the reduction was about 4%. Pharmacoeconomic analysis on mild and moderate patients has pointed out that about 50% of the total ICS treatments (814,692 € on 1,658,164 €) is related to the ICS element, and so considered inappropriate costs.
CONCLUSION: Economic differences between the two periods have highlighted a minor mean costs for Cohort 2, underlining an improvement in the adherence to the GOLD guidelines in the last period.

Keywords

COPD; GOLD guidelines; Adherence

Full Text:

HTML PDF

References

  • Mannino DM, Brown C, Giovino GA. Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiple-cause mortality data. Am J Respir Crit Care Med 1997; 156: 814-8; http://dx.doi.org/10.1164/ajrccm.156.3.9702026
  • Mathers CD, Loncar D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Med 2006; 3: e442; http://dx.doi.org/10.1371/journal.pmed.0030442
  • Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Update 2013
  • Pauwels RA, Buist AS, Calverley PM, et al.; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76; http://dx.doi.org/10.1164/ajrccm.163.5.2101039
  • World Health Report. Geneva: World Health Organization
  • Rycroft CE, Heyes A, Lanza L, et al. Epidemiology of COPD: a literature review. Int J Chron Obstruct Pulmon Dis 2012; 7: 457-94; http://dx.doi.org/10.2147/COPD.S32330
  • Gini R, Francesconi P, Mazzaglia G, et al. Chronic disease prevalence from Italian administrative databases in the VALORE project: a validation through comparison of population estimates with general practice databases and national survey. BMC Public Health 2013; 13: 15; http://dx.doi.org/10.1186/1471-2458-13-15
  • Indagini Multiscopo ISTAT sulle famiglie. ISTAT, 2010
  • Mathers C, Boerma T, Ma Fat D. The Global Burden of Disease: 2004 Update. World Health Organization 2008. Disponibile su www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf (ultimo accesso luglio 2013)
  • European Respiratory Society. European Lung White Book: Huddersfield, European Respiratory Society Journals, Ltd; 2003
  • Reid DJ, Pham NT. Emerging Therapeutic Options for the Management of COPD. Clin Med Insights Circ Respir Pulm Med 2013; 7: 7-15; http://dx.doi.org/10.4137/CCRPM.S8140
  • Katz P, Pegoraro V. L’utilizzo dei corticosteroidi nei pazienti con la bronco pneumopatia cronica ostruttiva: aspetti epidemiologici ed economici. Farmeconomia e percorsi terapeutici 2009; 10: 139-148
  • Cazzola M, Bettoncelli G, Sessa E, et al. Primary care of the patient with chronic obstructive pulmonary disease in Italy. Respir Med 2009; 103: 582-8; http://dx.doi.org/10.1016/j.rmed.2008.10.017
  • Asche CV, Leader S, Plauschinat C, et al. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis 2012; 7: 201-9; http://dx.doi.org/10.2147/COPD.S25805
  • Sharif R, Cuevas CR, Wang Y, et al., Guideline adherence in management of stable chronic obstructive pulmonary disease. Respir Med 2013; 107: 1046-52; http://dx.doi.org/10.1016/j.rmed.2013.04.001
  • Jebrak G. COPD routine management in France: Are guidelines used in clinical practice? Rev Mal Respir 2010; 27: 11-8; http://dx.doi.org/10.1016/j.rmr.2009.08.002
  • Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2013
  • Database IMS Health, Sell Out Italia consuntivo anno 2012, consultato in maggio 2013
  • American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-121

Refbacks

  • There are currently no refbacks.




© SEEd srl